Tianjin University of Traditional Chinese Medicine, Tianjin City 301617, China.
Department of Cardiology, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin City 300250, China.
Biosci Rep. 2019 Feb 27;39(2). doi: 10.1042/BSR20190022. Print 2019 Feb 28.
Previous studies investigate the relationship between peroxisome proliferator-activated receptor γ-2 () gene Pro12Ala polymorphisms and risk of hypertension. However, the number of available studies was extremely limited. We updated this evidence and gave more significant results. We performed comprehensive computer-based searches in the PubMed, Web of Science, Embase, Google Scholar, the Cochrane library, Wanfang database, China National Knowledge Infrastructure, and China Biological Medicine Database. All studies that reported the association between the PPARγ2Pro12Ala polymorphisms and hypertension were identified. Twenty-one studies were finally included in the present study. In the domain model, the PPARγ1Pro12Ala polymorphism was not associated with hypertension (odds ratio (OR) = 0.85, 95% confidence interval (CI): 0.71-1.03, =0.108). The significant relationship was found in the recessive model (OR = 0.67, 95% CI: 0.53-0.85), in the additive model (OR = 0.61, 95% CI: 0.48-0.77), and in the allele genetic model (OR = 0.81, 95% CI: 0.66-0.99). Subgroup analysis indicated that the PPARγ1Pro12Ala polymorphism from the all gene models was also not related to the risk of hypertension in Caucasians. In Asians, however, the results (=0.002; = 57.6%) suggested a significant relationship between PPARγ1Pro12Ala and hypertension in the domain model (OR = 0.80, 95% CI: 0.65-0.99), in the recessive model (OR = 0.57, 95% CI: 0.44-0.75), in the additive model (OR = 0.51, 95% CI: 0.39-0.66), and in the allele model (OR = 0.75, 95% CI: 0.60-0.94). The PPARγ1Pro12Ala polymorphism could affect the risk of primary hypertension amongst Asians. The A allele gene was a protective genotype for primary hypertension. The PPARγ1Pro12Ala polymorphism was not associated with hypertension amongst Caucasians.
先前的研究调查了过氧化物酶体增殖物激活受体 γ-2()基因 Pro12Ala 多态性与高血压风险之间的关系。然而,可用的研究数量极其有限。我们更新了这方面的证据,并得出了更有意义的结果。我们在 PubMed、Web of Science、Embase、Google Scholar、Cochrane 图书馆、万方数据库、中国国家知识基础设施和中国生物医学数据库中进行了全面的计算机检索。确定了所有报告过氧化物酶体增殖物激活受体 γ2Pro12Ala 多态性与高血压之间关联的研究。最终有 21 项研究纳入本研究。在显性模型中,PPARγ1Pro12Ala 多态性与高血压无关(比值比(OR)=0.85,95%置信区间(CI):0.71-1.03,=0.108)。在隐性模型(OR=0.67,95%CI:0.53-0.85)、加性模型(OR=0.61,95%CI:0.48-0.77)和等位基因遗传模型(OR=0.81,95%CI:0.66-0.99)中存在显著关系。亚组分析表明,所有基因模型的 PPARγ1Pro12Ala 多态性与白种人高血压的风险也无关。然而,在亚洲人中,结果(=0.002;=57.6%)表明,在显性模型(OR=0.80,95%CI:0.65-0.99)、隐性模型(OR=0.57,95%CI:0.44-0.75)、加性模型(OR=0.51,95%CI:0.39-0.66)和等位基因模型(OR=0.75,95%CI:0.60-0.94)中,PPARγ1Pro12Ala 与高血压之间存在显著关系。PPARγ1Pro12Ala 多态性可能会影响亚洲人原发性高血压的风险。A 等位基因是原发性高血压的保护基因型。PPARγ1Pro12Ala 多态性与白种人高血压无关。